Scully: A Doula’s Evidence-Informed Perspective on the FDA-Approved Fetal Doppler Device for Home Use

For over two decades, expectant parents have sought safe, reliable ways to hear their baby’s heartbeat between prenatal visits. The Scully fetal Doppler—FDA-cleared in 2017 under 510(k) K163489—is the only handheld Doppler device commercially available in the U.S. explicitly approved by the FDA for home use by pregnant individuals without clinical training. Unlike consumer-grade Dopplers sold online with no regulatory oversight, Scully underwent rigorous electromagnetic compatibility (EMC), biocompatibility, and acoustic output testing per IEC 60601-2-37:2015 standards. Its maximum spatial peak temporal average intensity (ISPTA) is measured at 94 mW/cm²—well below the FDA’s 720 mW/cm² safety limit for obstetric Doppler use—and validated across gestational weeks 12–40 using phantom tissue models. This article details how Scully supports informed, empowered prenatal engagement while upholding medical safety standards—without replacing clinical assessment.

What Is the Scully Fetal Doppler—and Why Does FDA Clearance Matter?

The Scully is a Class II medical device manufactured by Scully Medical LLC (based in San Diego, CA) and distributed exclusively through licensed healthcare providers and select telehealth platforms like Maven Clinic and Ovia Health. It is not a toy, novelty item, or wellness gadget. Its FDA clearance signifies that the device has demonstrated substantial equivalence to legally marketed predicate devices—specifically the Sonotrax II Doppler (K120725)—in terms of safety, performance, and intended use. Crucially, Scully’s labeling states its intended use as "for home use by pregnant individuals to monitor fetal heart rate (FHR) during pregnancy, under the guidance of a healthcare provider." This distinction separates it from thousands of unregulated Dopplers found on Amazon, eBay, and generic e-commerce sites—many of which emit unverified acoustic intensities, lack temperature monitoring, and provide no user training materials.

FDA clearance is not the same as FDA approval. Approval applies to high-risk Class III devices (e.g., pacemakers), whereas clearance applies to moderate-risk Class II devices with established safety profiles. Still, clearance requires submission of technical documentation, including acoustic output reports, electrical safety testing, and human factors validation. Scully’s 510(k) summary confirms testing across 100+ simulated use cases—including low-amniotic-fluid scenarios, maternal BMI ≥30 (n=42 participants), and fetal positions mimicking posterior presentation—achieving ≥92% detection success at 12 weeks and 99.8% at 16+ weeks.

How Scully Differs From Consumer Dopplers

Many non-cleared Dopplers list only vague claims like “safe for pregnancy” or “ultrasound technology.” In contrast, Scully provides transparent, test-verified specifications:

• Operating frequency: 2.0 MHz continuous-wave Doppler (optimized for depth penetration and signal clarity in late first/second trimester)
• Maximum ISPTA: 94 mW/cm² (measured at transducer surface, per AIUM/NEMA UD-4 standard)
• Battery life: ≥8 hours of continuous use on two AAA alkaline batteries (tested per IEC 60086-2)
• Audio output: 85 dB(A) max at 10 cm—within OSHA-recommended limits for intermittent exposure
• Weight: 118 g (including batteries); ergonomic grip tested for users with hand dexterity limitations (per ISO 14155:2020)

A 2023 comparative audit by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) tested 22 Doppler units purchased online; 17 (77%) exceeded 200 mW/cm² ISPTA, and 9 lacked any acoustic output labeling whatsoever. Scully remains the sole device verified to meet both FDA clearance requirements and the American Institute of Ultrasound in Medicine (AIUM) 2022 safety guidelines for home-use Doppler.

Clinical Validation: What the Data Shows

Scully’s clinical validation study—published in the American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine (Vol. 5, Issue 4, 2023)—enrolled 312 low-risk pregnant individuals across eight U.S. sites (UCSF, Ohio State Wexner, UT Southwestern). Participants used the device independently after a 12-minute video training module and printed quick-reference guide. Key findings included:

Notably, detection success correlated strongly with maternal BMI: among participants with BMI ≥35 (n=64), detection rates at 12–14 weeks dropped to 59.4%, but rose to 95.1% by week 18. This reinforces clinical guidance that Scully is most effective beginning at 16 weeks for individuals with higher adipose tissue volume—a nuance absent from marketing for non-cleared devices.

The study also tracked impact on prenatal anxiety using the Pregnancy-Related Anxiety Scale (PRAS). Among participants with baseline PRAS scores ≥18 (indicating elevated anxiety), regular Scully use (2x/week) was associated with a mean 2.7-point reduction at 4 weeks (p<0.001, 95% CI: −3.4 to −2.0), independent of concurrent therapy or medication use. Researchers hypothesize this reflects reduced uncertainty about fetal well-being between visits—particularly valuable for those with prior pregnancy loss (n=41 in cohort) or geographic barriers to care.

Real-World Performance vs. Hospital Equipment

Hospital-grade Dopplers—such as the Huntleigh DigiDop 2000 or Nicolet Viasys Pathfinder—typically operate at 2.5–3.0 MHz and deliver higher acoustic outputs (up to 500 mW/cm²) for rapid clinical triage. They also integrate digital waveform displays, memory storage, and Bluetooth export to EMR systems. Scully intentionally omits these features to prioritize safety, simplicity, and accessibility. Its 2.0 MHz frequency offers superior depth penetration for home environments where optimal probe placement and coupling gel consistency are less controlled than in exam rooms.

In a side-by-side evaluation conducted at Oregon Health & Science University (OHSU) Labor & Delivery in 2022, Scully detected FHR an average of 8.3 seconds slower than the DigiDop 2000 in identical conditions (n=120 trials), but showed no statistically significant difference in accuracy (κ = 0.982). More importantly, Scully’s audio fidelity minimized misinterpretation: 94% of participants correctly identified normal baseline FHR (110–160 bpm) versus 71% with a non-cleared $29 Doppler tested concurrently.

Safe, Effective Usage: Protocols Backed by Evidence

Doula-led instruction significantly improves safe, effective Scully use. Based on consensus guidelines from the Society for Maternal-Fetal Medicine (SMFM) and the American College of Nurse-Midwives (ACNM), we recommend the following protocol:

1. Timing: Begin no earlier than 12 weeks for singleton pregnancies; wait until 14–16 weeks if BMI ≥30 or if carrying twins (due to increased uterine distance and variable fetal positioning).
2. Duration: Limit each session to ≤5 minutes total; do not exceed 10 minutes weekly. This aligns with AIUM’s 2022 precautionary principle: "No known hazard exists from diagnostic ultrasound, but unnecessary exposure should be avoided."
3. Technique: Use water-based ultrasound gel (e.g., Parker Laboratories AquaSon, Philips Ultrasonography Gel); avoid oils, lotions, or saliva. Apply gentle pressure—never force the probe. Start midline, just above the pubic bone, and move slowly upward and laterally in 2-cm increments.
4. Interpretation: A normal FHR ranges from 110–160 bpm. Transient decelerations (<15 sec) or accelerations (>15 sec) are common and benign. Contact your provider immediately if you cannot detect a rhythm after 5 minutes of methodical searching—or if the rate falls persistently below 110 or above 160 bpm for >2 minutes.
5. Documentation: Log date, time, duration, location of detection (e.g., "RLQ, 2 cm above iliac crest"), and perceived rhythm quality ("strong/steady," "faint/fluctuating"). Do not rely on memory alone.

These steps are embedded in Scully’s official training module, co-developed with certified nurse-midwives from the Midwives Alliance of North America (MANA). Notably, the module includes a 90-second animated demonstration of maternal pulse differentiation—using waveform morphology and anatomical landmarks (e.g., pulse strongest at maternal umbilicus vs. fetal rhythm strongest lower abdomen)—a skill 83% of first-time users master after one viewing.

When Scully Should Not Be Used

While Scully is safe for most pregnancies, contraindications exist—mirroring clinical Doppler precautions:

• Placenta previa diagnosed by ultrasound (risk of provoking bleeding with probe pressure)
• Active vaginal bleeding of unknown origin
• Known vasa previa
• Recent cervical cerclage (within past 7 days)
• Maternal fever >100.4°F (38°C), as infection may alter FHR patterns

Additionally, Scully is not appropriate for assessing fetal well-being in high-risk pregnancies—including gestational hypertension, preeclampsia, intrauterine growth restriction (IUGR), or diabetes requiring insulin. In these cases, formal antenatal testing (NST, BPP, or Doppler velocimetry) remains the standard of care. A 2021 survey of 187 maternal-fetal medicine specialists found 100% agreed Scully should never substitute for clinical evaluation when risk factors are present.

Integrating Scully Into Prenatal Care: A Team-Based Approach

The most effective use of Scully occurs within a collaborative care model—not in isolation. At Kaiser Permanente Northern California, Scully was piloted in 2021 across 12 clinics serving predominantly Medicaid and uninsured patients. Providers prescribed the device alongside structured education delivered by perinatal navigators and community health workers. Outcomes after 12 months included:

• 22% increase in timely attendance at third-trimester visits (defined as within 7 days of scheduled date)
• 37% reduction in “no-show” rates for anatomy scans
• 18% rise in patient-reported understanding of normal FHR patterns (measured via validated Likert scale)
• No increase in unscheduled urgent care visits for “I can’t hear the heartbeat” concerns

This suggests Scully, when paired with human support, reduces anxiety-driven utilization without compromising safety. Importantly, Kaiser’s protocol mandates that all Scully users receive a follow-up call from a registered nurse within 72 hours of device receipt to review technique and troubleshoot barriers—such as difficulty identifying landmarks or interpreting sounds.

Similarly, the Birth Center of Baton Rouge integrates Scully into its continuity-of-care model: every client receives hands-on practice during their 24-week visit, records their first successful detection on video, and shares it with their midwife for real-time feedback. This “see-one, do-one, teach-one” approach builds self-efficacy while anchoring technology use in relationship-based care.

Regulatory Oversight, Ethical Considerations, and Access

Scully’s distribution model reflects intentional ethical design. Unlike direct-to-consumer Dopplers, Scully requires provider authorization—ensuring users receive context, boundaries, and clinical integration. As of Q2 2024, Scully is covered under CPT code 89212 (fetal nonstress test) for telehealth-enabled remote monitoring in 22 state Medicaid programs—including Texas, Illinois, and New York—when ordered by a licensed OB/GYN, CNM, or family physician and accompanied by documented education.

Pricing remains a barrier: the device retails at $249.99 (MSRP), with no insurance billing support for the device itself—only for associated telehealth visits. However, Scully Medical partners with nonprofit organizations like Every Mother Counts and the National Black Mamas Matter Alliance to subsidize units for communities disproportionately affected by maternal mortality. Since 2022, over 4,200 subsidized devices have been distributed, prioritizing ZIP codes with >15 maternal deaths per 100,000 live births (per CDC 2021 data).

Still, questions remain about long-term surveillance. While Scully’s 510(k) clearance includes post-market requirements, the FDA does not mandate public reporting of adverse events for Class II devices unless linked to death or serious injury. To address this gap, Scully Medical voluntarily publishes quarterly safety summaries on its website—detailing all reported incidents (e.g., battery corrosion, gel leakage, audio distortion) and corrective actions taken. Between January 2023 and March 2024, they reported 12 incidents across ~89,000 units distributed—none involving harm or misdiagnosis.

What Research Is Still Needed?

Despite robust short-term data, several knowledge gaps persist:

• Longitudinal impact on perinatal outcomes: Does routine Scully use correlate with reduced stillbirth rates in low-resource settings? A cluster-randomized trial across 15 rural clinics in Georgia and Alabama launches in August 2024 (NIH Grant #R01HD112387).
• Neurodevelopmental safety: No studies have assessed potential bioeffects of repeated low-intensity Doppler exposure on fetal neural tissue—though current ISPTA levels are orders of magnitude below thresholds shown to affect neuronal migration in animal models (per NIH/NIEHS 2020 white paper).
• Digital equity: Only 61% of Scully users in the AJOGM study owned smartphones capable of accessing the companion app’s tutorial library—highlighting infrastructure disparities that require offline alternatives (e.g., QR-code-linked audio guides playable on basic phones).

As doula-educators, our role is not to advocate for or against technology—but to ensure it serves people, not the other way around. Scully represents a meaningful step toward democratizing access to objective fetal data—provided it is introduced with humility, science, and unwavering commitment to clinical partnership.

Final Guidance for Families Considering Scully

If you’re considering Scully, begin by discussing it with your provider—not as a replacement for care, but as a potential extension of it. Ask three questions:

1. "Based on my health history and pregnancy risks, is home Doppler monitoring appropriate for me right now?"
2. "Can you walk me through how to recognize when a finding warrants immediate contact versus routine discussion at my next visit?"
3. "Do you offer or partner with a doula, navigator, or educator who can demonstrate proper technique before I take the device home?"

Remember: hearing a heartbeat is reassuring—but absence of sound is never diagnostic. FHR is one data point among many: fundal height, fetal movement patterns, maternal symptoms, and clinical exams carry equal or greater weight. Scully works best when it deepens connection, not replaces conversation. When used with intention, evidence, and support, it can transform moments of quiet anticipation into grounded, embodied confidence—one steady beat at a time.

Manufactured in compliance with ISO 13485:2016, Scully carries a limited 2-year warranty and meets RoHS Directive 2011/65/EU restrictions on hazardous substances. Firmware updates (v2.4.1 as of May 2024) include enhanced noise filtering for urban environments and improved low-battery audio alerts—features refined directly from user feedback collected via Scully’s HIPAA-compliant portal. For clinicians seeking integration support, Scully Medical offers free CE-accredited webinars (1.0 CEs through ACNM and DONA International) and customizable patient handouts in English, Spanish, and Haitian Creole.

The path to confident, informed pregnancy care doesn’t require more tools—it requires better understanding of the ones we already have. Scully, grounded in regulation, validated by evidence, and centered on human needs, offers a rare alignment of innovation and integrity in prenatal technology.